{"status": "OK", "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved.", "response": {"docs": [{"word_count": 984, "slideshow_credits": null, "multimedia": [], "news_desk": null, "pub_date": "2010-07-13T12:45:49Z", "source": "The New York Times", "web_url": "http://prescriptions.blogs.nytimes.com/2010/07/13/f-d-a-review-of-diet-pill-pleases-investors/", "blog": [], "_id": "4fd39bda8eb7c8105d8dae9d", "headline": {"kicker": "Prescriptions", "main": "F.D.A. Review of Diet Pill Relieves Investors"}, "subsection_name": null, "abstract": "The regulatory agency released its examination of the safety and effectiveness of Qnexa, in advance of an advisory panel on Thursday.", "section_name": "Health", "byline": {"original": "By ANDREW POLLACK", "person": [{"rank": 1, "firstname": "Andrew", "lastname": "POLLACK", "role": "reported", "organization": ""}]}, "print_page": null, "document_type": "blogpost", "type_of_material": "Blog", "keywords": [{"rank": "1", "value": "News", "name": "type_of_material"}], "lead_paragraph": "Chances for the approval of the first new drug in years to treat obesity seemed to increase Tuesday morning after the Food and Drug Administration released its review of the safety and effectiveness of Vivus's pill, Qnexa.", "snippet": "The regulatory agency released its examination of the safety and effectiveness of Qnexa, in advance of an advisory panel on Thursday."}], "meta": {"offset": 0, "hits": 1, "time": 39}}}